Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.

The Journal of antimicrobial chemotherapy - 2 Aug 2023

Brenner Bluma G, Oliveira Maureen, Ibanescu Ruxandra-Ilinca, Routy Jean-Pierre, Thomas Réjean

Abstract excerpt

OBJECTIVES: The NNRTI doravirine has been recently approved for the first-line treatment of HIV-infected patients, eliciting favourable responses against viruses bearing the K103N, Y181C and G190A mutations. This study used in vitro drug selections to elaborate the breadth of doravirine responses against viruses bearing NNRTI and NRTI resistance-associated mutations (RAMs). METHODS: WT clinical isolates (n = 6)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Reverse Transcriptase

Share to HIV Seropositivity

Share to Lamivudine

Share to Reverse Transcriptase Inhibitors

Share to Rilpivirine

Source

Identifiers

PMID: 37303226
DOI: 10.1093/jac/dkad184

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.PMID 37303226Read ↗

Cell culture selections reveal favourable drug resistance profiles for doravirine and islatravir.Semantic proximity Read ↗

In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.Semantic proximity Read ↗

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.Semantic proximity Read ↗

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.Semantic proximity Read ↗

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.Semantic proximity Read ↗

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.Semantic proximity Read ↗

Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.Semantic proximity Read ↗

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to DoravirineSemantic proximity Read ↗

K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.Semantic proximity Read ↗

Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.Semantic proximity Read ↗

Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug ResistanceSemantic proximity Read ↗

In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.